KOPRAN Stock Overview
An integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Kopran Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹199.55 |
| 52 Week High | ₹369.70 |
| 52 Week Low | ₹198.00 |
| Beta | 0.58 |
| 11 Month Change | -29.90% |
| 3 Month Change | -35.50% |
| 1 Year Change | -24.51% |
| 33 Year Change | -22.97% |
| 5 Year Change | 483.48% |
| Change since IPO | 137.56% |
Recent News & Updates
The Market Doesn't Like What It Sees From Kopran Limited's (NSE:KOPRAN) Earnings Yet As Shares Tumble 29%
Nov 18
Kopran Limited's (NSE:KOPRAN) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 14Recent updates
The Market Doesn't Like What It Sees From Kopran Limited's (NSE:KOPRAN) Earnings Yet As Shares Tumble 29%
Nov 18Kopran Limited's (NSE:KOPRAN) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 14Kopran (NSE:KOPRAN) Has Announced A Dividend Of ₹3.00
Aug 20Insufficient Growth At Kopran Limited (NSE:KOPRAN) Hampers Share Price
Jul 31Does Kopran (NSE:KOPRAN) Have A Healthy Balance Sheet?
Jun 12Here's Why Kopran (NSE:KOPRAN) Has A Meaningful Debt Burden
Jan 05Here's Why Kopran (NSE:KOPRAN) Has A Meaningful Debt Burden
Jun 03Kopran's (NSE:KOPRAN) Dividend Will Be Increased To ₹3.00
Jul 14Here's Why I Think Kopran (NSE:KOPRAN) Might Deserve Your Attention Today
Nov 25Should You Be Adding Kopran (NSE:KOPRAN) To Your Watchlist Today?
Jun 10These 4 Measures Indicate That Kopran (NSE:KOPRAN) Is Using Debt Safely
Mar 21If You Had Bought Kopran (NSE:KOPRAN) Stock A Year Ago, You Could Pocket A 327% Gain Today
Feb 14Kopran Limited's (NSE:KOPRAN) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 24Is Kopran (NSE:KOPRAN) A Risky Investment?
Dec 20
Introducing Kopran (NSE:KOPRAN), The Stock That Soared 338% In The Last Year
Nov 15Kopran Limited's (NSE:KOPRAN) Stock Is Going Strong: Is the Market Following Fundamentals?
Oct 11Is Kopran (NSE:KOPRAN) Using Too Much Debt?
Sep 07Shareholder Returns
| KOPRAN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -11.6% | -0.2% | 0.3% |
| 1Y | -24.5% | 40.5% | 27.3% |
Return vs Industry: KOPRAN underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: KOPRAN underperformed the Indian Market which returned 27.3% over the past year.
Price Volatility
| KOPRAN volatility | |
|---|---|
| KOPRAN Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: KOPRAN's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: KOPRAN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 842 | Surendra Somani | www.kopran.com |
Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular.
Kopran Limited Fundamentals Summary
| KOPRAN fundamental statistics | |
|---|---|
| Market cap | ₹9.63b |
| Earnings (TTM) | ₹528.93m |
| Revenue (TTM) | ₹6.36b |
18.2x
P/E Ratio1.5x
P/S RatioIs KOPRAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KOPRAN income statement (TTM) | |
|---|---|
| Revenue | ₹6.36b |
| Cost of Revenue | ₹4.15b |
| Gross Profit | ₹2.21b |
| Other Expenses | ₹1.69b |
| Earnings | ₹528.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.97 |
| Gross Margin | 34.83% |
| Net Profit Margin | 8.32% |
| Debt/Equity Ratio | 25.0% |
How did KOPRAN perform over the long term?
See historical performance and comparison